Serum matrix metalloproteinase-9 (MMP9) and amyloid-beta protein precursor (APP) as potential biomarkers in children with Fragile-X syndrome: A cross sectional study

CONCLUSIONS: Screening for circulating biomarkers in the absence of FXS genetic diagnosis is justified. Our study is the first to evaluate both MMP9 and APP in FXS suspected children in a clinical setting and to assess their correlation with disease presentation and severity.PMID:37797798 | DOI:10.1016/j.clinbiochem.2023.110659

Source: Clinical Biochemistry - October 5, 2023 Category: Biochemistry Authors: Mohamed H Y Bekheet Lamiaa A Mansour Rasha H Elkaffas Mona A Kamel Mohamed A Elmonem Source Type: research